Leerink Swann reiterated their outperform rating on shares of Johnson & Johnson (NYSE:JNJ) in a research note issued to investors on Wednesday morning, The Fly reports. They currently have a $160.00 price target on the stock, down from their previous price target of $175.00. Leerink Swann also issued estimates for Johnson & Johnson’s FY2018 earnings at $8.15 EPS, Q1 2019 earnings at $2.27 EPS and Q3 2019 earnings at $2.12 EPS. The analysts noted that the move was a valuation call.
Several other analysts have also recently commented on JNJ. Vetr upgraded shares of Johnson & Johnson from a hold rating to a buy rating and set a $147.14 target price for the company in a research report on Wednesday, December 20th. JPMorgan Chase cut shares of Johnson & Johnson from an overweight rating to a neutral rating in a research report on Tuesday, January 2nd. Royal Bank of Canada reiterated a buy rating on shares of Johnson & Johnson in a research report on Tuesday, January 9th. Wells Fargo reiterated an outperform rating and set a $160.00 target price (up previously from $155.00) on shares of Johnson & Johnson in a research report on Friday, January 12th. Finally, Credit Suisse Group set a $154.00 price target on shares of Johnson & Johnson and gave the company a hold rating in a report on Monday, January 22nd. Five research analysts have rated the stock with a sell rating, eight have given a hold rating and ten have assigned a buy rating to the company’s stock. The company has a consensus rating of Hold and an average price target of $142.98.
Shares of Johnson & Johnson stock opened at $127.72 on Wednesday. The firm has a market cap of $350,226.03, a price-to-earnings ratio of 17.50, a price-to-earnings-growth ratio of 2.08 and a beta of 0.74. Johnson & Johnson has a 52 week low of $121.11 and a 52 week high of $148.32. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.41 and a quick ratio of 1.12.
Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, April 17th. The company reported $2.06 EPS for the quarter, beating the consensus estimate of $2.00 by $0.06. The company had revenue of $20.01 billion during the quarter, compared to analysts’ expectations of $19.50 billion. Johnson & Johnson had a net margin of 1.58% and a return on equity of 30.05%. The business’s revenue for the quarter was up 12.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.83 EPS. sell-side analysts forecast that Johnson & Johnson will post 8.11 EPS for the current year.
In related news, VP Paulus Stoffels sold 155,342 shares of the company’s stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $129.86, for a total value of $20,172,712.12. Following the completion of the transaction, the vice president now directly owns 357,906 shares of the company’s stock, valued at approximately $46,477,673.16. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 0.22% of the stock is currently owned by corporate insiders.
A number of hedge funds and other institutional investors have recently made changes to their positions in JNJ. Goodman Financial Corp acquired a new position in shares of Johnson & Johnson during the 4th quarter worth about $104,000. Harding Loevner LP acquired a new position in shares of Johnson & Johnson during the 2nd quarter worth about $106,000. Stelac Advisory Services LLC acquired a new position in shares of Johnson & Johnson during the 4th quarter worth about $108,000. IHT Wealth Management LLC boosted its stake in shares of Johnson & Johnson by 46.4% during the 2nd quarter. IHT Wealth Management LLC now owns 10,942 shares of the company’s stock worth $122,000 after buying an additional 3,467 shares during the last quarter. Finally, Mountain Capital Investment Advisors Inc acquired a new position in shares of Johnson & Johnson during the 2nd quarter worth about $124,000. 67.23% of the stock is owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION NOTICE: This news story was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this news story on another domain, it was stolen and republished in violation of US and international trademark & copyright law. The original version of this news story can be accessed at https://www.dispatchtribunal.com/2018/04/19/johnson-johnson-jnj-given-outperform-rating-at-leerink-swann.html.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.